XERTESA Trademark

Trademark Overview


On Tuesday, February 14, 2017, a trademark application was filed for XERTESA with the United States Patent and Trademark Office. The USPTO has given the XERTESA trademark a serial number of 87335713. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 12, 2020. This trademark is owned by Allergan Sales, LLC. The XERTESA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; Pharmaceutical preparations used in connection with and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of pre...
xertesa

General Information


Serial Number87335713
Word MarkXERTESA
Filing DateTuesday, February 14, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 12, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 11, 2017

Trademark Statements


Goods and ServicesPharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; Pharmaceutical preparations used in connection with and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
Translation of Words in MarkThe word "XERTESA" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 21, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Sales, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Party NameAllergan Sales, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressIrvine, CA 92612

Trademark Events


Event DateEvent Description
Tuesday, October 13, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, October 12, 2020ABANDONMENT - NO USE STATEMENT FILED
Tuesday, March 10, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 9, 2020EXTENSION 5 GRANTED
Friday, February 28, 2020EXTENSION 5 FILED
Monday, March 9, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, February 28, 2020TEAS EXTENSION RECEIVED
Wednesday, July 17, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 15, 2019EXTENSION 4 GRANTED
Monday, July 15, 2019EXTENSION 4 FILED
Monday, July 15, 2019TEAS EXTENSION RECEIVED
Saturday, February 16, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 14, 2019EXTENSION 3 GRANTED
Thursday, February 14, 2019EXTENSION 3 FILED
Thursday, February 14, 2019TEAS EXTENSION RECEIVED
Thursday, September 6, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 4, 2018EXTENSION 2 GRANTED
Tuesday, September 4, 2018EXTENSION 2 FILED
Tuesday, September 4, 2018TEAS EXTENSION RECEIVED
Thursday, January 25, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 23, 2018EXTENSION 1 GRANTED
Tuesday, January 23, 2018EXTENSION 1 FILED
Tuesday, January 23, 2018TEAS EXTENSION RECEIVED
Tuesday, September 5, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 11, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 11, 2017PUBLISHED FOR OPPOSITION
Wednesday, June 21, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, May 12, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, May 12, 2017EXAMINER'S AMENDMENT ENTERED
Friday, May 12, 2017NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, May 12, 2017EXAMINERS AMENDMENT E-MAILED
Friday, May 12, 2017EXAMINERS AMENDMENT -WRITTEN
Tuesday, May 9, 2017ASSIGNED TO EXAMINER
Tuesday, February 21, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, February 17, 2017NEW APPLICATION ENTERED IN TRAM